Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists check how donor skin graft heals in breast reconstruction

NCT ID NCT05744414

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examines how AlloMend®, a graft made from donated human skin, integrates with a patient's own tissue during breast reconstruction. Researchers will analyze tissue samples from 30 women who had the graft placed with a tissue expander, looking for signs of cell growth, blood vessel formation, and healing. The goal is to better understand how the body accepts the graft, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AlloMend® acellular dermal matrix (a graft material made from donated human skin, processed to support tissue regeneration)
What this could lead to
If successful, this study could confirm that AlloMend® safely integrates with the body, supporting its use in breast reconstruction procedures.
What could go wrong
This is a small, early-stage study (30 participants) focused on tissue analysis, not on proving clinical benefits. Results may not apply to all patients or guarantee better outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2023

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults 18 years of age or greater who have undergone a pre-pectoral placement of tissue expanders for breast reconstruction and will have a histological evaluation of the AlloMend® Acellular Dermal Matrix and native tissue at time of permanent breast implantation

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥18 years of age; * AlloMend® Acellular Dermal Matrix used during the initial prepectoral placement of tissue expanders for breast reconstruction; * Is scheduled or will be scheduled for a procedure to exchange the tissue expander for permanent breast implant; * Can understand the requirements of the study, has provided written, informed consent, and to comply with the study protocol. Exclusion Criteria: * Mentally compromised (e.g., being currently treated for a psychiatric disorder, senile dementia, Alzheimer's disease) in a manner that would compromise his or her ability to consent to participate in the clinical study; * Subjects who, in the opinion of the investigator, would not be able or willing to comply with the protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast implant; complications, infection or inflammation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Infections Inflammation mastitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Janiga MDs Plastic Surgery and Cosmetic Center

    Reno, Nevada, 89521, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.